|
[1]
|
Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Willeit, P., Ridker, P.M., Nestel, P.J., et al. (2018) Baseline and On-Statin Treatment Lipoprotein(a) Levels for Prediction of Cardiovascular Events: Individual Patient-Data Me-ta-Analysis of Statin Outcome Trials. The Lancet, 392, 1311- 1320. [Google Scholar] [CrossRef]
|
|
[3]
|
Wang, Z.W., Li, M., Li, J.J., et al. (2022) Association of Lipoprotein(a) with All-Cause and Cause-Specific Mortality: A Prospective Cohort Study. European Journal of Internal Medicine, 106, 63-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
van der Valk, F.M., Bekkering, S., Kroon, J., et al. (2016) Oxi-dized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 134, 611-624. [Google Scholar] [CrossRef]
|
|
[5]
|
Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. Journal of the American College of Cardiology, 73, 2150-2162. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Bourgeois, R., Bourgault, J., Despres, A.A., et al. (2021) Lipopro-tein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. Metabolites, 11, 459. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Salpeter, S.R., Walsh, J.M.E., Ormiston, T.M., et al. (2006) Me-ta-Analysis: Effect of Hormone-Replacement Therapy on Components of the Metabolic Syndrome in Postmenopausal Women. Diabetes Obesity & Metabolism, 8, 538-554. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Osnabrugge, R.L.J., Mylotte, D., Head, S.J., et al. (2013) Aortic Stenosis in the Elderly Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study. Journal of the American College of Cardiology, 62, 1002-1012. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Schmidt, K., Noureen, A., Kronenberg, F., et al. (2016) Thematic Review Series: Lipoprotein(a): Coming of Age at Last Structure, Function, and Genetics of Lipoprotein(a). Journal of Li-pid Research, 57, 1339-1359. [Google Scholar] [CrossRef]
|
|
[10]
|
Lamina, C. and Kronenberg, F. (2013) The Mysterious Lipoprotein(a) Is Still Good for a Surprise. The Lancet Diabetes & Endocrinology, 1, 170-172. [Google Scholar] [CrossRef]
|
|
[11]
|
Jawi, M.M., Frohlich, J. and Chan, S.Y. (2020) Lipopro-tein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. Journal of Lipids, 2020, Article ID: 3491764. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
McCormick, S.P.A. and Schneider, W.J. (2019) Lipoprotein(a) Catabo-lism: A Case of Multiple Receptors. Pathology, 51, 155-164. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Brown, M.S. and Goldstein, J.L. (1986) A Receptor-Mediated Pathway for Cholesterol Homeostasis. Science, 232, 34-47. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Romagnuolo, R., Scipione, C.A., Boffa, M.B., et al. (2015) Lipopro-tein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. Journal of Biological Chemistry, 290, 11649-11662. [Google Scholar] [CrossRef]
|
|
[15]
|
Tam, S.P., Zhang, X. and Koschinsky, M.L. (1996) Interaction of a Recombinant Form of Apolipoprotein[a] with Human Fi-broblasts and with the Human Hepatoma Cell Line HepG2. Journal of Lipid Research, 37, 518-533. [Google Scholar] [CrossRef]
|
|
[16]
|
Romagnuolo, R., Scipione, C.A., Marcovina, S.M., et al. (2017) Roles of the Low Density Lipoprotein Receptor and Related Receptors in Inhibition of Lipoprotein(a) Internaliza-tion by Proprotein Convertase Subtilisin/Kexin Type 9. PLOS ONE, 12, e0180869. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Villard, E.F., Thedrez, A., Blankenstein, J., et al. (2016) PCSK9 Modulates the Secretion but Not the Cellular Uptake of Lipoprotein(a) ex Vivo: An Effect Blunted by Alirocumab. JACC: Basic to Translational Science, 1, 419-427. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Chemello, K., Beeske, S., Trang Tran, T.T., et al. (2020) Lipo-protein(a) Cellular Uptake ex Vivo and Hepatic Capture in Vivo Is Insensitive to PCSK9 Inhibition with Alirocumab. JACC: Basic to Translational Science, 5, 549-557. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Chemello, K., Garcia-Nafria, J., Gallo, A., et al. (2021) Lipopro-tein Metabolism in Familial Hypercholesterolemia. Journal of Lipid Research, 62, Article ID: 100062. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Blom, D.J., Harada-Shiba, M., Rubba, P., et al. (2020) Efficacy and Safety of Alirocumab in Adults with Homozygous Familial Hypercholesterolemia: The Odyssey HoFH Trial. Journal of the American College of Cardiology, 76, 131-142. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Croyal, M., Tran, T.T., Blanchard, R.H., et al. (2018) PCSK9 Inhi-bition with Alirocumab Reduces Lipoprotein(a) Levels in Nonhuman Primates by Lowering Apolipoprotein(a) Produc-tion Rate. Clinical Science, 132, 1075-1083. [Google Scholar] [CrossRef]
|
|
[22]
|
Youssef, A., Clark, J.R., Marcovina, S.M., et al. (2022) Apo(a) and ApoB Interact Noncovalently within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, 289-304. [Google Scholar] [CrossRef]
|
|
[23]
|
Watts, G.F., Chan, D.C., Pang, J., et al. (2020) PCSK9 Inhi-bition with Alirocumab Increases the Catabolism of Lipoprotein(a) Particles in Statin-Treated Patients with Elevated Lip-oprotein(a). Metabolism, 107, Article ID: 154221. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Yang, X.P., Amar, M.J., Vaisman, B., et al. (2013) Scavenger Receptor-BI Is a Receptor for Lipoprotein(a). Journal of Lipid Research, 54, 2450-2457. [Google Scholar] [CrossRef]
|
|
[25]
|
Hoekstra, M., Chen, H.Y., Rong, J., et al. (2021) Genome-Wide Associ-ation Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 41, 458-464. [Google Scholar] [CrossRef]
|
|
[26]
|
Croyal, M., Blanchard, V., Ouguerram, K., et al. (2020) VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 819-829. [Google Scholar] [CrossRef]
|
|
[27]
|
Capoulade, R., Torzewski, M., Mayr, M., et al. (2020) ApoCIII-Lp(a) Complexes in Conjunction with Lp(a)-OxPL Predict Rapid Progression of Aortic Stenosis. Heart, 106, 738-745. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Hopewell, J.C., Haynes, R. and Baigent, C. (2018) The Role of Lipoprotein (a) in Chronic Kidney Disease. Journal of Lipid Research, 59, 577-585. [Google Scholar] [CrossRef]
|
|
[29]
|
Kamstrup, P.R., Tybjaerg-Hansen, A. and Nordestgaard, B.G. (2013) Ex-treme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction. Journal of the American College of Cardiol-ogy, 61, 1146-1156. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Saeed, A. and Virani, S.S. (2018) Lipoprotein(a) and Cardiovascu-lar Disease: Current State and Future Directions for an Enigmatic Lipoprotein. Frontiers in Bioscience-Landmark, 23, 1099-1112. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Saeed, A., Sun, W.S., Agarwala, A., et al. (2019) Lipoprotein(a) Levels and Risk of Cardiovascular Disease Events in Individuals with Diabetes Mellitus or Prediabetes: The Atheroscle-rosis Risk in Communities Study. Atherosclerosis, 282, 52-56. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Erqou, S., Thompson, A., Di Angelantonio, E., et al. (2010) Apolipoprotein(a) Isoforms and the Risk of Vascular Disease Systematic Review of 40 Studies Involving 58,000 Participants. Journal of the American College of Cardiology, 55, 2160-2167. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Craig, W.Y., Neveux, L.M., Palomaki, G.E., et al. (1998) Lipopro-tein(a) as a Risk Factor for Ischemic Heart Disease: Meta-Analysis of Prospective Studies. Clinical Chemistry, 44, 2301-2306. [Google Scholar] [CrossRef]
|
|
[34]
|
Binder, C.J., Papac-Milicevic, N. and Witztum, J.L. (2016) Innate Sensing of Oxidation-Specific Epitopes in Health and Disease. Nature Reviews Immunology, 16, 485-497. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Di Fusco, S.A., Arca, M., Scicchitano, P., et al. (2022) Lipoprotein(a): A Risk Factor for Atherosclerosis and an Emerging Therapeutic Target. Heart, 109, 18-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Di Gioia, M., Spreafico, R., Springstead, J.R., et al. (2020) En-dogenous Oxidized Phospholipids Reprogram Cellular Metabolism and Boost Hyperinflammation. Nature Immunology, 21, 42-53. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Schnitzler, J.G., Hoogeveen, R.M., Ali, L., et al. (2020) Athero-genic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 126, 1346-1359. [Google Scholar] [CrossRef]
|
|
[38]
|
Boffa, M.B., Marar, T.T., Yeang, C., et al. (2019) Potent Reduction of Plasma Lipoprotein(a) with an Antisense Oligonucleotide in Human Subjects Does Not Affect ex Vivo Fi-brinolysis. Journal of Lipid Research, 60, 2082-2089. [Google Scholar] [CrossRef]
|
|
[39]
|
Nordestgaard, B.G. and Langsted, A. (2016) Lipoprotein(a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Lipid Research, 57, 1953-1975. [Google Scholar] [CrossRef]
|
|
[40]
|
Di Maio, S., Lamina, C., Coassin, S., et al. (2022) Lipoprotein(a) and SARS-CoV-2 Infections: Susceptibility to Infections, Ischemic Heart Disease and Thromboembolic Events. Journal of Internal Medicine, 291, 101-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Enkhmaa, B., Petersen, K.S., Kris-Etherton, P.M., et al. (2020) Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? Nutrients, 12, 2024. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Bittner, V.A., Szarek, M., Aylward, P.E., et al. (2020) Effect of Aliro-cumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. Journal of the American College of Cardiology, 75, 133-144. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Koren, M.J., Moriarty, P.M., Baum, S.J., et al. (2022) Preclinical Development and Phase 1 Trial of a Novel siRNA Targeting Lipoprotein(a). Nature Medicine, 28, 96-103. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Viney, N.J., van Capelleveen, J.C., Geary, R.S., et al. (2016) Antisense Oligonucleotides Targeting Apolipoprotein(a) in People with Raised Lipoprotein(a): Two Randomised, Dou-ble-Blind, Placebo-Controlled, Dose-Ranging Trials. The Lancet, 388, 2239-2253. [Google Scholar] [CrossRef]
|
|
[45]
|
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 382, 244-255. [Google Scholar] [CrossRef]
|
|
[46]
|
Tsimikas, S., Gordts, P., Nora, C., et al. (2020) Satin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Pokrovsky, S.N., Afanasieva, O.I. and Ezhov, M.V. (2020) Thera-peutic Apheresis for Management of Lp(a) Hyperlipoproteinemia. Current Atherosclerosis Reports, 22, 68. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Waldmann, E. and Parhofer, K.G. (2016) Lipoprotein Apheresis to Treat Elevated Lipoprotein(a). Journal of Lipid Research, 57, 1751-1757. [Google Scholar] [CrossRef]
|
|
[49]
|
Moriarty, P.M., Gray, J.V. and Gorby, L.K. (2019) Lipoprotein Apheresis for Lipoprotein(a) and Cardiovascular Disease. Journal of Clinical Lipidology, 13, 894-900. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Khan, T.Z., Hsu, L.Y., Arai, A.E., et al. (2017) Apheresis as Novel Treatment for Refractory Angina with Raised Lipoprotein(a): A Randomized Controlled Cross-Over Trial. European Heart Journal, 38, 1561-1569. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Trinder, M., Paruchuri, K., Haidermota, S., et al. (2022) Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. Journal of the American College of Cardiol-ogy, 79, 617-628. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
O’Donoghue, M.L., Fazio, S., Giugliano, R.P., et al. (2019) Lipo-protein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights from the FOURIER Trial. Circulation, 139, 1483-1492. [Google Scholar] [CrossRef]
|
|
[53]
|
Bergmark, B.A., O’Donoghue, M.L., Murphy, S.A., et al. (2020) An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Ste-nosis in the Fourier Trial. JAMA Cardiology, 5, 709-713. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Katzmann, J.L., Packard, C.J., Chapman, M.J., et al. (2020) Targeting RNA with Antisense Oligonucleotides and Small Interfering RNA JACC State-of-the-Art Review. Journal of the American College of Cardiology, 76, 563-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Tsimikas, S., Viney, N.J., Hughes, S.G., et al. (2015) Antisense Therapy Targeting Apolipoprotein(a): A Randomised, Double-Blind, Placebo-Controlled Phase 1 Study. The Lancet, 386, 1472-1483. [Google Scholar] [CrossRef]
|
|
[56]
|
Nissen, S.E., Wolski, K., Balog, C., et al. (2022) Single As-cending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels. Journal of the American Medical Association, 327, 1679-1687. [Google Scholar] [CrossRef] [PubMed]
|